Digital Health · Regulatory & Market Access
Healthcare Quality Measurement in 2026: The Complete Guide for Medtech and Health IT Companies
How quality metrics translate into reimbursement, which measure sets matter, and why health technology companies that ignore the mechanics of quality measurement are leaving money — and clinical credibility — on the table.
OZOP Surgical Editorial · April 2026 · 20 min read
45%
National Spend Driven by Federal/State Programmes
$750B
Potential Annual Savings from Quality Improvement
9%
Max Penalty for Lowest-Performing Providers
38%
Americans Covered by Federal Programmes
Why Quality Measurement Should Be on Every Medtech Company’s Radar
Quality metrics are not an abstraction reserved for hospital administrators and insurance executives. They are the financial architecture that determines how healthcare providers get paid, how health plans retain revenue, and — critically for the medtech and health IT industry — how your customers justify the purchase of your product. If your technology improves clinical outcomes but those improvements do not register in the specific quality measures embedded in your customers’ reimbursement contracts, you have a value proposition problem that no sales deck can solve.
The US healthcare system has historically delivered worse outcomes than peer nations despite higher spending. The gap between what the system spends and what it achieves in patient outcomes represents an estimated $750 billion in annual waste — and quality measurement programmes are the primary mechanism through which payers, regulators, and providers are attempting to close it. Federal and state programmes now drive approximately 45 percent of national healthcare expenditure, and the quality measurement frameworks they use cascade into commercial insurance contracts, provider negotiations, and health plan accreditation requirements.
Quality measurement is not an afterthought for health technology companies — it is the mechanism through which clinical value is converted into financial value for your customers.
For health technology companies — whether you build surgical robotics platforms, AI-powered diagnostic tools, clinical decision support systems, or EHR modules — understanding how quality metrics work is essential to positioning your product effectively, pricing it credibly, and demonstrating ROI in the language your buyers actually use. This guide covers the full landscape: who develops the measures, how they are structured, how they translate into payment, and where the opportunities are for medtech and health IT companies to build quality measurement into their products from day one.
Two Ways Health Technology Affects Quality Performance
Health technology products improve quality measure performance through two distinct pathways, and understanding which pathway your product addresses is fundamental to how you position it commercially.
Pathway 1
Changing Clinical Care
The product facilitates changes in how clinical care is delivered — directly affecting the measured processes or outcomes. An AI diagnostic tool that identifies at-risk patients earlier, a surgical navigation system that reduces complication rates, or a clinical decision support module that increases guideline-concordant treatment.
Pathway 2
Improving Documentation
The product improves the capture and coding of data elements required by the measure specification. An EHR module that ensures correct coding of clinical encounters, a data integration layer that surfaces demographic information required for population stratification, or automated reporting tools that reduce documentation gaps.
Both pathways create genuine financial value for customers. Improved performance on quality measures — whether through better care delivery or more accurate capture of care that is already being delivered — translates into quality incentive payments, higher ratings in performance systems that feed into reimbursement, and stronger positioning for future contracts. For many widely-used quality measures, these financial benefits accrue even when the product improves measured processes rather than ultimate health outcomes. That is not a loophole — it is how the system is designed.
The Precision Problem: Why Broad Clinical Improvement Does Not Always Move the Measure
This is where most health technology companies make their first — and most expensive — strategic error. A product may deliver genuine clinical improvement across a broad patient population, but if that improvement does not cross the specific thresholds defined in the relevant quality measure specification, it will not register as improved performance in the customer’s reimbursement programme.
Consider a concrete example. A health technology company develops a chronic disease management platform and can demonstrate that 20 percent of patients respond to its intervention, achieving a measurable clinical improvement. Impressive on its face. However, the relevant quality measure only counts patients who cross a specific clinical threshold — for instance, moving from above a particular biomarker level to below it. Patients who start well above the threshold and improve but remain above it are not counted. Patients who start below the threshold and improve further are also not counted. Only the patients in the narrow band around the threshold — who improve enough to cross it — register as improved performance.
Example: How Measure Thresholds Filter Clinical Improvement
Hypothetical: 1,000 patients. Product affects 20% (200 patients). Measure only reimburses for patients crossing a specific clinical threshold.
400
Far above threshold
Improve but still above → Not counted
200
Near threshold
20% respond = 40 cross → 40 counted
400
Already below threshold
Improve further → Not counted
Product improves health for 200 patients
→
Measure recognises improvement for 40 patients
The implication is clear: health technology companies that want to make a credible quality measurement argument need to understand the exact specification of the measures their customers use — including the numerator and denominator definitions, the threshold values, the eligible population criteria, and the exclusion rules. Broad statements about clinical improvement are insufficient. The value proposition must be articulated in the precise terms of the measure specification.
The Landscape: Who Develops the Measures, and Which Ones Matter
The quality measurement ecosystem involves multiple overlapping entities that develop, maintain, and implement measure sets. Most health technology companies only need to understand a handful of specific measures — but they need to understand those measures deeply. The key players operate in a layered system where federal agencies fund and mandate measurement, independent organisations develop and maintain the specifications, and payers and providers implement them in contracts and workflows.
🏛️
Federal Healthcare Agency (CMS)
The dominant funder of measure development and the largest single user of quality measures. Directly covers 38 percent of Americans through federal insurance programmes and regulates coverage for an additional 4 percent through insurance exchanges. Contracts with independent organisations to oversee measure development and maintenance.
🔬
Consensus-Based Entity (CBE)
The federally designated body that assesses quality measures and oversees the process of maintaining key measure sets used in fee-for-service programmes. Reviews measures for validity, reliability, and feasibility. Assigns identification numbers that are referenced across payment programmes.
📊
Quality Assurance Bodies (e.g., HEDIS Maintainers)
Private organisations that develop and maintain widely-used clinical quality measure sets. These measures are embedded in federal, state, and commercial contracts. The transition toward digital quality measures — relying on standardised coding systems beyond traditional claims data — is being driven by these organisations.
Major Quality Measure Sets and Where They Appear
| Measure Set | Used In | Maintained By |
|---|---|---|
| HEDIS | Federal, state, and commercial payment programmes | Private quality assurance body (annual review) |
| Core Sets (Adult, Child, Behavioural Health) | State-level reporting for public insurance programmes | Federal agency via expert workgroup |
| Star Ratings | Managed federal insurance plan performance assessment | Consensus body advisory process; federal rulemaking |
| Fee-for-Service Measure Sets | Various federal payment programmes (hospital, physician, specialty) | Consensus body; annual federal rulemaking |
| Exchange Quality Rating System | Qualified health plans on insurance exchanges | Federal agency via rulemaking |
| Universal Foundation | Reference tool for convergence across measure sets | Federal agency (no defined update schedule) |
Measure sets overlap significantly in topic areas — preventive care, chronic disease management (diabetes, hypertension), and behavioural health are common across all major sets.
Anatomy of a Quality Metric: Numerators, Denominators, and Why the Details Are Everything
Every quality measure is a precisely defined specification describing who is being measured (the denominator), what counts as successful performance (the numerator), over what time period, and with what exclusions. These specifications are developed through resource-intensive processes designed to ensure the measure is valid, reliable, feasible, and comparable across different entities and time periods. Understanding the structure of these specifications is not optional for health technology companies — it is the difference between a credible quality claim and a misleading one.
| Component | Definition | Why It Matters for Health Tech |
|---|---|---|
| Denominator | The eligible population where the process or outcome could occur | Defines who your product needs to reach. If your user base does not overlap with the denominator population, the measure is irrelevant to your value proposition. |
| Numerator | The subset of the denominator for whom the desired process or outcome occurred | Defines what success looks like. Your product must demonstrably move patients into the numerator to claim quality improvement. |
| Exclusions | Patients removed from the denominator due to clinical circumstances (e.g., hospice, death) | Reduces the measurable population. If your product disproportionately serves excluded populations, the measurable impact shrinks. |
| Measurement Period | The calendar period during which performance is assessed (typically one year) | Timing matters. Providers are most focused on closing performance gaps in Q3 and Q4 of the measurement year — a sales cycle insight. |
| Data Source | Claims, encounter data, EHR data, surveys, or digital sources | Determines how your product’s impact will be captured. The industry is transitioning toward digital quality measures using standardised coding (LOINC, SNOMED) beyond traditional claims-based measurement. |
The shift toward digital quality measures is particularly significant for health technology companies. Historically, quality measurement relied on claims and encounter data — billing records that capture what was done and coded, not necessarily what was clinically relevant. Digital measures draw on EHR data, using standardised terminology systems, which opens the door for technology companies whose products capture structured clinical data to contribute directly to quality measurement infrastructure. Companies that design their data capture to align with the coding systems used in quality specifications — matching the specific fields, value sets, and definitions — add measurable value to their customers’ quality reporting workflows.
How Quality Measures Translate Into Actual Reimbursement
Quality measures become financially consequential through value-based payment programmes — structured arrangements where providers or payers receive financial rewards for high performance and face penalties for low performance. The design of these programmes is complex, and the financial impact of any single measure depends on three critical variables: the total weight assigned to quality within the programme, the number of measures sharing that weight, and the mechanism by which performance translates into payment (direct performance payment versus quality gates that unlock access to other savings).
| Programme | Population | Measures | Financial Mechanism |
|---|---|---|---|
| Merit-Based Incentive | Fee-for-service patients served by eligible physicians | ~200 (select 6+) | Quality = 30% of final score → payment adjustment; budget-neutral (penalties fund bonuses) |
| Advanced Alternative Models | Patients in accountable care organisations | 6–12 | Quality = 50% of final score; not budget-neutral → higher potential upside for strong performers |
| Managed Plan Star Ratings | Beneficiaries in managed insurance plans | 30 (Part C) + 12 (Part D) | 4–5 star rating → 5% benchmark increase + higher rebate retention; avg. rebate value >$2,300/enrollee |
| Hospital Inpatient Quality | Fee-for-service hospital patients | 19 + eCQMs | Pay-for-reporting + value-based purchasing; up to 2% payment adjustment |
| Renal Disease Quality | Dialysis facility patients | 18 | Up to 2% payment reduction based on performance |
| State Managed Care | State-insured beneficiaries in managed care | Varies by state | Withheld payments returned based on quality; plan-level public reporting planned by 2028 |
The lowest-performing participants face penalties as high as 9 percent of their covered service payments. That makes quality improvement not a luxury but a risk management imperative — and a compelling sales argument for technology that demonstrably moves the needle.
A critical nuance for health technology companies: the entity participating in the payment programme may not be the entity that directly uses your product. Health plans frequently delegate quality performance requirements to providers through their contracts. To identify your actual buyers, you need to understand both which entities are accountable for performance and which entities have the operational ability to affect it. A product that helps a specialist practice improve documentation of a specific procedure may ultimately generate financial value for the managed care plan that contracts with that practice — but the purchase decision may sit with the practice, the plan, or a health system that employs the specialist.
The Annual Cycle: When Measures Change and When Customers Buy
Quality measure sets are re-evaluated annually, with new measures added and outdated measures retired on a regular schedule. This cycle creates both risk and opportunity for health technology companies. If your value proposition depends on a measure that is at risk of being retired, you have a commercial vulnerability. If you can demonstrate impact on a newly added measure before competitors do, you have a first-mover advantage. Understanding the timeline lets you anticipate customer needs and align product development accordingly.
Illustrative Annual Cycle for Major Federal Quality Programmes
Note: Timing is approximate and subject to change. Some programmes may forgo notice-and-comment rulemaking under current administrative policy.
The practical implication for sales and product teams: the period when prior-year performance data is released — typically mid-year — is when customers are most acutely aware of their quality gaps and most receptive to purchasing improvement solutions. The period from Q3 through year-end is when providers are most focused on closing care gaps before the measurement period closes. Aligning your marketing, sales outreach, and product release cycles to this annual rhythm can meaningfully improve conversion.
Five Strategic Actions for Health Technology Companies
1
Start with the measure specification, not the clinical claim
Before positioning your product around quality improvement, identify the exact measures your customers use and read the full specifications. Understand the numerator, denominator, exclusions, and data sources. Build your value story in the language of the measure, not in generalised clinical outcomes.
2
Design data capture around quality specifications from day one
Configure your product to track processes and outcomes using the same code definitions, value sets, and field structures used in relevant quality measures. Even if your product cannot calculate formal performance results, aligning data capture with measure parameters adds material value for customers.
3
Monitor the annual measure set cycle for risks and opportunities
Track the annual rulemaking and measure review processes. If a measure your product addresses is being considered for retirement, you have a commercial vulnerability to manage. If a new measure is being added in your clinical area, you have a first-mover opportunity to capture.
4
Engage the regulatory process — comments can make a difference
Proposed rules are open for public comment, and regulators are sometimes willing to make technical adjustments — adding a specific code to an eligible services list, adjusting implementation timelines — when presented with data-driven arguments. This is a low-cost, high-optionality channel for health technology companies.
5
Map the accountability chain to identify your actual buyer
The entity accountable for quality performance in a payment programme may not be the entity that uses your product. Health plans delegate requirements to providers. Providers delegate to specialists. Understanding this chain — and where your product creates measurable impact — determines your go-to-market strategy.
Frequently Asked Questions
What is a quality measure in healthcare?
A quality measure is a precisely defined specification that assesses whether participants in the healthcare system — payers, hospitals, physician practices — are delivering effective care. It captures a snapshot of performance or quantifies change over time by looking for the presence or absence of specific clinical or administrative indicators in patient records. These measures are used in reimbursement programmes to adjust payments based on performance.
Why should medical device and health IT companies care about quality measurement?
Quality measurement directly affects your customers’ revenue. Improved performance on quality measures can generate incentive payments, higher plan ratings that increase reimbursement benchmarks, stronger positioning for contract renewals, and avoidance of financial penalties. If your product improves clinical care or documentation in ways that align with specific quality measures, that alignment is a measurable part of your ROI story. If it does not align, your clinical impact may not translate into financial value for your buyer.
What is the difference between a numerator and a denominator in a quality measure?
The denominator defines the eligible population — the group of patients where a specific process or outcome could occur. The numerator defines the subset of that population for whom the desired process or outcome actually occurred. Performance is calculated as the proportion of the denominator that appears in the numerator. Your product needs to demonstrably move patients from the denominator into the numerator to claim quality improvement.
What are digital quality measures and why do they matter for health tech?
Digital quality measures draw on structured clinical data from electronic health records and other digital sources, using standardised coding systems like LOINC and SNOMED in addition to traditional claims codes. This transition opens opportunities for health technology products that capture structured clinical data to contribute directly to quality measurement — provided their data fields and definitions align with the measure specifications.
How often do quality measure sets change?
Most major measure sets are reviewed annually, with new measures added and existing measures retired through a structured process that typically spans from late autumn through the following spring or summer. Changes are proposed in advance and open for public comment, giving companies that monitor the cycle time to prepare. Final changes are published in annual payment rules or through programme-specific guidance documents.
Can a health tech product improve quality measure performance without improving health outcomes?
Yes, in specific circumstances. Quality measures assess both care processes and outcomes. A product that improves documentation of care processes — ensuring that guideline-concordant actions are properly coded and captured in the clinical record — can improve measured performance even if the underlying clinical care has not changed. This is not gaming the system; it is closing the gap between care delivered and care documented, which is a recognised problem in quality measurement.
What is a value-based payment programme?
A value-based payment programme is a reimbursement arrangement that adjusts provider or plan payments based on quality performance rather than volume of services delivered. These programmes may offer financial bonuses for high performance, impose penalties for low performance, or use quality metrics as gates that determine access to shared savings from reduced total cost of care. They are the primary mechanism through which quality measures become financially consequential.
What is the financial penalty for poor quality performance?
Penalties vary by programme. In the merit-based incentive programme for physicians, the lowest-performing participants can face penalties of up to 9 percent of their covered service payments. Hospital programmes can impose payment reductions of up to 2 percent. Managed care plans that fail to achieve four- or five-star ratings miss out on benchmark increases and higher rebate retention — a loss that can represent thousands of dollars per enrolled beneficiary.
What if my product targets a condition that does not have a quality measure?
If your product serves a population too small or specialised to be covered by major payment programme measures — such as rare diseases — you can look for validated measures in dedicated databases that catalogue measures beyond the major payment sets. While measures not linked to payment incentives may be less commercially compelling, they provide a validated benchmark for demonstrating impact. Building a product and assuming a quality measure will be developed later is a high-risk strategy — measure development is slow, resource-intensive, and not guaranteed to result in inclusion in payment programmes.
How can health tech companies influence quality measure development?
Each quality measure has a designated steward responsible for maintaining its specifications. Companies that identify potential improvements to an existing measure can contact the steward with a data-driven proposal. Simple changes — like adding a code for a newly approved treatment in an established category — can sometimes be adopted with minimal process. Companies can also submit comments on proposed rules when measures are being considered for addition to or removal from major programmes. While individual comments rarely prompt sweeping changes, they can influence technical details that matter for health technology adoption.
OZOP Surgical is an independent healthcare technology publication. This analysis is editorial commentary and does not constitute medical, legal, or regulatory advice. Quality measurement policies are subject to change — always consult current programme guidance for the most recent specifications and requirements. For the full technical specifications referenced in this guide, consult the relevant federal programme documentation at cms.gov. © 2026 OZOP Surgical. All rights reserved.